Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes.

Emmanuelle GrasTommaso Francesco AielloMariana ChumbitaAntonio Gallardo-PizarroPatricia Monzó-GalloChristian Teijón-LumbrerasMaria Suárez-LledóLaura MagnanoMontse TusetMaria Ángeles MarcosAlex Soriano Carolina García-Vidal

Published in: The Journal of antimicrobial chemotherapy (2024)

The extended course of remdesivir, combined with other active therapies for COVID-19 infection, was well tolerated. Cure and virus negativity were obtained in all these high-risk patients.

Keyphrases

end stage renal disease
coronavirus disease
sars cov
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
adipose tissue
metabolic syndrome
glycemic control